179 related articles for article (PubMed ID: 18441333)
1. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.
Iwamoto M; Kost JT; Mistry GC; Wenning LA; Breidinger SA; Marbury TC; Stone JA; Gottesdiener KM; Bloomfield DM; Wagner JA
J Clin Pharmacol; 2008 Jun; 48(6):726-33. PubMed ID: 18441333
[TBL] [Abstract][Full Text] [Related]
2. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.
Radziszewski W; Lai E; Lazarus Shipitofsky N; Stroh M; Dishy V; Han L; Lewis W; Johnson-Levonas AO; Lutz R; Wagner J
Am J Ther; 2010; 17(1):8-16. PubMed ID: 20027105
[TBL] [Abstract][Full Text] [Related]
3. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer.
Munster PN; Rubin EH; Van Belle S; Friedman E; Patterson JK; Van Dyck K; Li X; Comisar W; Chodakewitz JA; Wagner JA; Iwamoto M
Clin Cancer Res; 2009 Nov; 15(22):7077-84. PubMed ID: 19887475
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of vardenafil and sildenafil on cardiac repolarization.
Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
[TBL] [Abstract][Full Text] [Related]
6. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.
Luo WL; Crumley T; Ebel D; Atiee GJ; Royalty J; Johnson-Levonas AO; Wagner J; Lai E
J Clin Pharmacol; 2010 Nov; 50(11):1273-9. PubMed ID: 20107202
[TBL] [Abstract][Full Text] [Related]
7. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.
Bloomfield DM; Krishna R; Hreniuk D; Hickey L; Ghosh K; Bergman AJ; Miller J; Gutierrez MJ; Stoltz R; Gottesdiener KM; Herman GA; Wagner JA
J Clin Pharmacol; 2009 Aug; 49(8):937-46. PubMed ID: 19602719
[TBL] [Abstract][Full Text] [Related]
8. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
[TBL] [Abstract][Full Text] [Related]
9. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
[TBL] [Abstract][Full Text] [Related]
10. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
11. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
12. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
13. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
[TBL] [Abstract][Full Text] [Related]
14. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
Malhotra BK; Glue P; Sweeney K; Anziano R; Mancuso J; Wicker P
Clin Pharmacol Ther; 2007 Mar; 81(3):377-85. PubMed ID: 17339867
[TBL] [Abstract][Full Text] [Related]
15. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals.
March B; Cardi T
Expert Opin Investig Drugs; 2009 Dec; 18(12):1807-15. PubMed ID: 19938897
[TBL] [Abstract][Full Text] [Related]
18. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants.
Zhang X; Jordan P; Cristea L; Salgo M; Farha R; Kolis S; Lee LS
J Clin Pharmacol; 2012 Apr; 52(4):520-9. PubMed ID: 21558456
[TBL] [Abstract][Full Text] [Related]
19. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Merschman SA; Strohmaier KM; Ramael S; Lasseter KC; Stone JA; Gottesdiener KM; Wagner JA
Clin Pharmacol Ther; 2008 Feb; 83(2):293-9. PubMed ID: 17713476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
